Processa Pharmaceuticals Inc (NASDAQ: PCSA) on Monday, plunged -47.59% from the previous trading day, before settling in for the closing price of $0.27. Within the past 52 weeks, PCSA’s price has moved between $0.15 and $1.22.
During the last 5-year period, the sales growth of Healthcare Sector giant was 22.65%. The company achieved an average annual earnings per share of 89.41%. With a float of $50.06 million, this company’s outstanding shares have now reached $52.86 million.
Processa Pharmaceuticals Inc (PCSA) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Processa Pharmaceuticals Inc is 11.62%, while institutional ownership is 3.14%. The most recent insider transaction that took place on Jan 27 ’25, was worth 9,889. In this transaction Director of this company bought 12,400 shares at a rate of $0.80, taking the stock ownership to the 12,400 shares. Before that another transaction happened on Jan 27 ’25, when Company’s Chief Executive Officer bought 87,200 for $0.80, making the entire transaction worth $69,542. This insider now owns 87,200 shares in total.
Processa Pharmaceuticals Inc (PCSA) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.74 earnings per share (EPS) for the period topping the consensus outlook (set at -0.92) by 0.18.
According to the Wall Street analysts, stocks earnings will be around 89.41% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 62.14% during the next five years compared to 22.65% growth over the previous five years of trading.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Trading Performance Indicators
Processa Pharmaceuticals Inc (PCSA) is currently performing well based on its current performance indicators. A quick ratio of 3.76 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.36, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.24 in one year’s time.
Technical Analysis of Processa Pharmaceuticals Inc (PCSA)
Looking closely at Processa Pharmaceuticals Inc (NASDAQ: PCSA), its last 5-days average volume was 3.46 million, which is a drop from its year-to-date volume of 8.57 million. As of the previous 9 days, the stock’s Stochastic %D was 31.23%.
During the past 100 days, Processa Pharmaceuticals Inc’s (PCSA) raw stochastic average was set at 6.85%, which indicates a significant decrease from 16.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0339 in the past 14 days, which was higher than the 0.0318 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3125, while its 200-day Moving Average is $0.2779. However, in the short run, Processa Pharmaceuticals Inc’s stock first resistance to watch stands at $0.2377. Second resistance stands at $0.3338. The third major resistance level sits at $0.3977. If the price goes on to break the first support level at $0.0777, it is likely to go to the next support level at $0.0138.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Key Stats
Market capitalization of the company is 8.01 million based on 56,644K outstanding shares. Right now, sales total 0 K and income totals -11,850 K. The company made 0 K in profit during its latest quarter, and -3,440 K in sales during its previous quarter.
